Daejeon, South Korea and Rockville, MD — October 31, 2025
Xcellon Biologics, a leading Antibody Drug Conjugate CDMO, announced a new partnership with IntoCell Inc. (KOSDAQ: 287840) to expand access to next-generation ADC linker-payload technologies. The collaboration combines IntoCell’s proprietary OHPAS platform with Xcellon’s ADC process development and manufacturing expertise to help innovators advance differentiated biologics more efficiently.
Read the full press release on Globe Newswire and Pharmaceutical Technology.
Under the agreement, IntoCell’s OHPAS drug-linker system, including duocarmycin and nexatecan payloads, will become part of Xcellon’s ADC development toolbox. Xcellon will support biotech and pharmaceutical programs through bioconjugation, analytical development, and scalable manufacturing designed to accelerate early-stage ADC pipelines.
“We’re excited to work with IntoCell, whose chemistry complements our end-to-end ADC development platform,” said Yuk Chun Chiu, Co-Founder and COO of Xcellon Biologics. “Integrating these linker-payload technologies lets our clients explore more options and move promising ADCs forward faster.”
“This partnership reflects our shared goal of expanding global access to innovative ADC technologies,” added Abhishake Chhibber, Board Member of Xcellon Biologics. “By combining IntoCell’s discovery chemistry with our flexible U.S.-based CDMO infrastructure, we’re helping bridge discovery and manufacturability.”
The IntoCell partnership further strengthens Xcellon’s global collaboration network focused on accelerating ADC development. By uniting advanced linker-payload chemistry with U.S.-based CDMO infrastructure, both companies aim to reduce early development bottlenecks and improve manufacturability for next-generation biologics.
Explore related capabilities and company information:
